SG10201811185YA - Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii - Google Patents

Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii

Info

Publication number
SG10201811185YA
SG10201811185YA SG10201811185YA SG10201811185YA SG10201811185YA SG 10201811185Y A SG10201811185Y A SG 10201811185YA SG 10201811185Y A SG10201811185Y A SG 10201811185YA SG 10201811185Y A SG10201811185Y A SG 10201811185YA SG 10201811185Y A SG10201811185Y A SG 10201811185YA
Authority
SG
Singapore
Prior art keywords
blood coagulation
coagulation factor
factor viii
decrease
activity
Prior art date
Application number
SG10201811185YA
Inventor
Koichiro Yoneyama
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG10201811185YA publication Critical patent/SG10201811185YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Abstract

9 PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF DECREASE OR LOSS OF ACTIVITY OF BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED BLOOD COAGULATION FACTOR VIII The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or 5 activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively. Figure 1
SG10201811185YA 2014-06-20 2015-03-31 Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii SG10201811185YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014127240 2014-06-20
JP2014226988 2014-11-07

Publications (1)

Publication Number Publication Date
SG10201811185YA true SG10201811185YA (en) 2019-01-30

Family

ID=54935230

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201811185YA SG10201811185YA (en) 2014-06-20 2015-03-31 Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
SG11201610581RA SG11201610581RA (en) 2014-06-20 2015-03-31 Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201610581RA SG11201610581RA (en) 2014-06-20 2015-03-31 Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii

Country Status (16)

Country Link
US (9) US20170253663A1 (en)
EP (2) EP3159006A4 (en)
JP (2) JP6663846B2 (en)
KR (1) KR20170015517A (en)
CN (1) CN106559987A (en)
AU (1) AU2015275440B2 (en)
BR (1) BR112016029316A2 (en)
CA (1) CA2951622C (en)
IL (1) IL249330B (en)
MX (1) MX2016016380A (en)
MY (1) MY189333A (en)
RU (1) RU2721910C2 (en)
SG (2) SG10201811185YA (en)
TW (2) TW201625299A (en)
WO (1) WO2015194233A1 (en)
ZA (1) ZA201700459B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
ES2568436T3 (en) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedure to control the blood pharmacokinetics of antibodies
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
AR080428A1 (en) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd FORMULATIONS STABILIZED LIQUID CONTAINERS OF ANTIBODIES
MY166429A (en) 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
KR102441231B1 (en) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 Method for producing polypeptide heteromultimer
TWI700300B (en) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII)
TWI701435B (en) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 Method to determine the reactivity of FVIII
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
UA126900C2 (en) * 2016-04-28 2023-02-22 Чугаі Сейяку Кабусікі Кайся Antibody-containing preparation
CN117986372A (en) * 2016-07-29 2024-05-07 中外制药株式会社 Bispecific antibodies exhibiting increased functional activity of alternative FVIII cofactors
SG11201901961SA (en) * 2016-09-06 2019-04-29 Chugai Pharmaceutical Co Ltd Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
CN110023339A (en) * 2016-09-23 2019-07-16 Csl有限公司 Coagulation factor binding protein and its application
WO2018181870A1 (en) * 2017-03-31 2018-10-04 公立大学法人奈良県立医科大学 Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
BR112020005834A2 (en) 2017-09-29 2020-09-24 Chugai Seiyaku Kabushiki Kaisha multispecific antigen binding molecule having blood clotting factor viii cofactor function (fviii) replacement activity, and pharmaceutical formulation containing said molecule as an active ingredient
US11787874B2 (en) 2017-11-15 2023-10-17 Novo Nordisk A/S Factor X binders enhancing FX activation
CA3123177A1 (en) 2018-12-21 2020-06-25 Kymab Limited Fixaxfx bispecific antibody with common light chain
WO2021070885A1 (en) * 2019-10-11 2021-04-15 中外製薬株式会社 Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition
CA3152701A1 (en) 2019-10-11 2021-04-15 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition
KR20230130560A (en) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Methods of administering fviii mimetic bispecidic antibodies once weekly
KR20230130561A (en) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Methods of administering fviii mimetic bispecidic antibodies every second week
KR20230130558A (en) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Methods of administering fviii mimetic bispecidic antibodies once monthly

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
FR2707189B1 (en) 1993-07-09 1995-10-13 Gradient Ass Method for treating combustion residues and installation for implementing said method.
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
ES2364266T3 (en) 1998-04-03 2011-08-30 Chugai Seiyaku Kabushiki Kaisha HUMANIZED ANTIBODY TOWARDS THE HUMAN TISSULAR FACTOR (TF) AND PROCEDURE TO BUILD THE HUMANIZED ANTIBODY.
ATE448301T1 (en) 2000-09-08 2009-11-15 Univ Zuerich COLLECTION OF PROTEINS WITH REPEATING SEQUENCES (REPEAT PROTEINS) THAT CONTAIN REPETITIVE SEQUENCE MODULES
JP2004526419A (en) 2000-10-16 2004-09-02 フィロス インク． Protein scaffolds for antibody mimics and other binding proteins
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
WO2005035754A1 (en) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005035753A1 (en) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
CA2957144C (en) 2005-04-08 2020-06-02 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
AR080428A1 (en) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd FORMULATIONS STABILIZED LIQUID CONTAINERS OF ANTIBODIES
BR112012031920A2 (en) * 2010-06-14 2017-05-16 Paion Deutschland Gmbh treatment of coagulopathies with hyperfibrinolysis.
MY166429A (en) * 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii

Also Published As

Publication number Publication date
CA2951622C (en) 2023-01-03
EP4218816A2 (en) 2023-08-02
SG11201610581RA (en) 2017-01-27
JP2020055864A (en) 2020-04-09
US20230174673A1 (en) 2023-06-08
CN106559987A (en) 2017-04-05
US20220073645A1 (en) 2022-03-10
TW201625299A (en) 2016-07-16
IL249330B (en) 2021-07-29
EP4218816A3 (en) 2023-09-13
MX2016016380A (en) 2017-04-06
MY189333A (en) 2022-02-04
TWI831106B (en) 2024-02-01
RU2017101705A (en) 2018-07-27
BR112016029316A2 (en) 2018-02-20
KR20170015517A (en) 2017-02-08
US20200407463A1 (en) 2020-12-31
US20240052060A1 (en) 2024-02-15
RU2017101705A3 (en) 2018-11-01
US20200157243A1 (en) 2020-05-21
ZA201700459B (en) 2021-07-28
WO2015194233A1 (en) 2015-12-23
NZ727218A (en) 2023-08-25
EP3159006A4 (en) 2018-01-03
IL249330A0 (en) 2017-02-28
US20190309090A1 (en) 2019-10-10
JP6663846B2 (en) 2020-03-13
CA2951622A1 (en) 2015-12-23
JPWO2015194233A1 (en) 2017-04-20
TW202241504A (en) 2022-11-01
EP3159006A1 (en) 2017-04-26
AU2015275440B2 (en) 2020-07-16
US20220324999A1 (en) 2022-10-13
RU2721910C2 (en) 2020-05-25
AU2015275440A1 (en) 2017-01-12
US20210238307A1 (en) 2021-08-05
US20170253663A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
SG10201811185YA (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MX2019002510A (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x.
TW201612167A (en) Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane -2-carboxamides as dipeptidyl peptidase 1 inhibitors
MX2017016134A (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease.
MX2023000796A (en) Pharmaceutical composition, methods for treating and uses thereof.
PH12016502352A1 (en) Pharmaceutical composition
MX2021002321A (en) Novel methods.
TW201613578A (en) Pharmaceutical combinations
EA201691918A1 (en) PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
EA201691656A2 (en) THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.
EA202193276A1 (en) METHODS FOR THE TREATMENT OF CHOLANGIOCARCINOMA
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
EA201892675A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ETHEPLIRSEN
MX2018003308A (en) Localized delivery of anti-fugetactic agent for treatment of cancer.
UA96488U (en) A method for treating disorders of hemovascular hemostasis in patients with ischemic heart disease